Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
10
03
2022
pubmed:
31
3
2022
medline:
13
4
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
The development of Alzheimer's disease therapeutics has been challenging, with 99% of clinical trials failing to find a significant difference between drug and placebo. While the quest continues for more effective treatments, there is emerging evidence that pharmacogenetic considerations are important factors in regard to metabolism, efficacy, and toxicity of drugs. Currently, there are five US Food and Drug Administration-approved drugs for the treatment of Alzheimer's disease; three acetylcholinesterase inhibitors, memantine, and aducanumab. Introducing a limited genetic panel consisting of APOE4, CYP2D6*10, and BChE*K would optimize acetylcholinesterase inhibitor therapy, facilitate immunotherapy risk assessment, and inform an amyloid-related imaging abnormality surveillance schedule. In view of the genetic heterogeneity of Alzheimer's disease identified in genome-wide association studies, pharmacogenetics is expected to play an increasing role in mechanism-specific treatment strategies and personalized medicine.
Identifiants
pubmed: 35352296
doi: 10.1007/s40263-022-00915-3
pii: 10.1007/s40263-022-00915-3
doi:
Substances chimiques
Apolipoprotein E4
0
Cholinesterase Inhibitors
0
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-376Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018;31(10):1161–9.
doi: 10.1016/j.amjmed.2018.01.022
Seripa D, D’Onofrio G, Panza F, et al. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011;14(5):491–500.
pubmed: 21958003
doi: 10.1089/rej.2011.1169
pmcid: 21958003
Xiao T, Jiao B, Zhang W, et al. Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease: a systematic review and meta-analysis. CNS Drugs. 2016;30(10):899–907.
pubmed: 27282366
doi: 10.1007/s40263-016-0356-1
pmcid: 27282366
Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021;53(9):1276–82.
pubmed: 34493870
doi: 10.1038/s41588-021-00921-z
pmcid: 34493870
Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51(3):404–13.
pubmed: 30617256
pmcid: 6836675
doi: 10.1038/s41588-018-0311-9
Banks SJ, Qiu Y, Fan CC, et al. Enriching the design of Alzheimer’s disease clinical trials: application of the polygenic hazard score and composite outcome measures. Alzheimers Dement (N Y). 2020;6(1):e12071.
Szigeti K, Ihnatovych I, Birkaya B, et al. CHRFAM7A: a human specific fusion gene, accounts for the translational gap for cholinergic strategies in Alzheimer’s disease. EBioMedicine. 2020;59:102892.
pubmed: 32818803
pmcid: 7452451
doi: 10.1016/j.ebiom.2020.102892
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.
pubmed: 24450890
doi: 10.1056/NEJMoa1312889
pmcid: 24450890
Zhong Y, Zheng X, Miao Y, et al. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci. 2013;345(3):222–6.
pubmed: 22986607
doi: 10.1097/MAJ.0b013e318255a8f9
pmcid: 22986607
Yaowaluk T, Senanarong V, Limwongse C, et al. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia. Pharmgenomics Pers Med. 2019;12:209–24.
pubmed: 31564952
pmcid: 6732559
Ketter N, Brashear HR, Bogert J, et al. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients. J Alzheimers Dis. 2017;57(2):557–73.
pubmed: 28269765
doi: 10.3233/JAD-160216
pmcid: 28269765
Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother. 1998;32(1):70–7.
pubmed: 9475825
doi: 10.1345/aph.17150
pmcid: 9475825
Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm. 1997;54(24):2805–10.
pubmed: 9428950
doi: 10.1093/ajhp/54.24.2805
pmcid: 9428950
Noetzli M, Guidi M, Ebbing K, et al. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit. 2013;35(2):270–5.
pubmed: 23503455
doi: 10.1097/FTD.0b013e318282ff02
pmcid: 23503455
Jasiecki J, Wasag B. Butyrylcholinesterase protein ends in the pathogenesis of Alzheimer’s disease: could BCHE genotyping be helpful in Alzheimer’s therapy? Biomolecules. 2019;9(10):592.
pmcid: 6843418
doi: 10.3390/biom9100592
Prestori F, Bonardi C, Mapelli L, et al. Gating of long-term potentiation by nicotinic acetylcholine receptors at the cerebellum input stage. PLoS ONE. 2013;8(5):e64828.
pubmed: 23741401
pmcid: 3669396
doi: 10.1371/journal.pone.0064828
Shen J, Wu J. Nicotinic cholinergic mechanisms in Alzheimer’s disease. Int Rev Neurobiol. 2015;124:275–92.
pubmed: 26472533
doi: 10.1016/bs.irn.2015.08.002
pmcid: 26472533
Lewis AS, van Schalkwyk GI, Bloch MH. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: a translational meta-analysis of rodent and human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:45–53.
pubmed: 28065843
pmcid: 5446073
doi: 10.1016/j.pnpbp.2017.01.001
Aracava Y, Pereira EF, Maelicke A, et al. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312(3):1195–205.
pubmed: 15522999
doi: 10.1124/jpet.104.077172
pmcid: 15522999
van Dyck CH. Anti-amyloid-beta monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83(4):311–9.
pubmed: 28967385
doi: 10.1016/j.biopsych.2017.08.010
Brashear HR, Ketter N, Bogert J, et al. Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies. J Alzheimers Dis. 2018;66(4):1409–24.
pubmed: 30412493
doi: 10.3233/JAD-180675
pmcid: 30412493
Miranda LF, Gomes KB, Tito PA, et al. Clinical response to donepezil in mild and moderate dementia: relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphisms. J Alzheimers Dis. 2017;55(2):539–49.
pubmed: 27716659
doi: 10.3233/JAD-160164
pmcid: 27716659
Rigaud AS, Traykov L, Latour F, et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics. 2002;12(5):415–20.
pubmed: 12142731
doi: 10.1097/00008571-200207000-00009
pmcid: 12142731
De Beaumont L, Pelleieux S, Lamarre-Theroux L, et al. Butyrylcholinesterase K and apolipoprotein E-varepsilon4 reduce the age of onset of Alzheimer’s disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects. J Alzheimers Dis. 2016;54(3):913–22.
pubmed: 27567841
doi: 10.3233/JAD-160373
pmcid: 27567841
Salloway S, Mintzer J, Cummings JL, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(6):421–32.
pubmed: 22930699
doi: 10.1177/1533317512454708
pmcid: 22930699
Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2008;25(5):445–50.
pubmed: 18401173
doi: 10.1159/000124752
pmcid: 18401173
Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20(4):254–61.
pubmed: 16103669
doi: 10.1159/000087371
pmcid: 16103669
Waring JF, Tang Q, Robieson WZ, et al. APOE-varepsilon4 carrier status and donepezil response in patients with Alzheimer’s disease. J Alzheimers Dis. 2015;47(1):137–48.
pubmed: 26402762
pmcid: 4923746
doi: 10.3233/JAD-142589
Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr Med Res Opin. 2006;22(3):483–94.
pubmed: 16574032
doi: 10.1185/030079906X89685
pmcid: 16574032
Blesa R, Aguilar M, Casanova JP, et al. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(4):248–54.
pubmed: 17132969
doi: 10.1097/01.wad.0000213880.93665.c7
Han HJ, Kim BC, Lee JY, et al. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients. Dement Geriatr Cogn Disord. 2012;34(3–4):167–73.
pubmed: 23051684
doi: 10.1159/000342927
Suh GH, Jung HY, Lee CU, et al. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21(1):33–9.
pubmed: 16254428
doi: 10.1159/000089217
Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12(2):69–77.
pubmed: 11173877
doi: 10.1159/000051238
Babic T, Mahovic Lakusic D, Sertic J, et al. ApoE genotyping and response to galanthamine in Alzheimer’s disease: a real life retrospective study. Coll Antropol. 2004;28(1):199–204.
pubmed: 15636076
MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. Int J Geriatr Psychiatry. 1998;13(9):625–30.
pubmed: 9777427
doi: 10.1002/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2
Wroolie TE, Kenna HA, Williams KE, et al. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. Acta Neurol Scand. 2009;119(3):172–9.
pubmed: 18705678
doi: 10.1111/j.1600-0404.2008.01084.x
Lu J, Wang X, Wan L, et al. Gene polymorphisms affecting the pharmacokinetics and pharmacodynamics of donepezil efficacy. Front Pharmacol. 2020;11:934.
pubmed: 32636753
pmcid: 7317019
doi: 10.3389/fphar.2020.00934
Han HJ, Kwon JC, Kim JE, et al. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer’s disease. Eur Neurol. 2015;73(1–2):23–8.
pubmed: 25376930
doi: 10.1159/000366198
Braga IL, Silva PN, Furuya TK, et al. Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2015;30(2):39–44.
doi: 10.1177/1533317514539540
Weng PH, Chen JH, Chen TF, et al. CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer’s disease. PLoS ONE. 2013;8(12):e84059.
pubmed: 24391883
pmcid: 3877150
doi: 10.1371/journal.pone.0084059
Clarelli F, Mascia E, Santangelo R, et al. CHRNA7 gene and response to cholinesterase inhibitors in an Italian cohort of Alzheimer’s disease patients. J Alzheimers Dis. 2016;52(4):1203–8.
pubmed: 27104904
doi: 10.3233/JAD-160074
pmcid: 27104904
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33.
pubmed: 24450891
pmcid: 4159618
doi: 10.1056/NEJMoa1304839
Salloway SP, Sperling R, Fox NC, et al. Long-term follow up of patients with mild-to-moderate Alzheimer’s disease treated with bapineuzumab in a phase III, open-label, extension study. J Alzheimers Dis. 2018;64(3):689–707.
pubmed: 29914022
doi: 10.3233/JAD-171157
pmcid: 29914022
Vandenberghe R, Rinne JO, Boada M, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.
pubmed: 27176461
pmcid: 4866415
doi: 10.1186/s13195-016-0189-7
Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):95.
pubmed: 29221491
pmcid: 5723032
doi: 10.1186/s13195-017-0318-y
Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.
pubmed: 27582220
doi: 10.1038/nature19323
pmcid: 27582220
Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241–9.
pubmed: 22305802
pmcid: 4063417
doi: 10.1016/S1474-4422(12)70015-7
Brody M, Liu E, Di J, et al. A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2016;54(4):1509–19.
pubmed: 27589523
doi: 10.3233/JAD-160369
pmcid: 27589523
Cummings JL, Cohen S, van Dyck CH, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889–97.
pubmed: 29695589
pmcid: 5962917
doi: 10.1212/WNL.0000000000005550
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.
pubmed: 33720637
pmcid: 33720637
doi: 10.1056/NEJMoa2100708
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
pubmed: 33865446
pmcid: 8053280
doi: 10.1186/s13195-021-00813-8
Turner RM, Park BK, Pirmohamed M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med. 2015;7(4):221–41.
pubmed: 25950758
pmcid: 4696409
doi: 10.1002/wsbm.1302
Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–22.
pubmed: 27528417
doi: 10.1038/nrg.2016.86
pmcid: 27528417
Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521–32.
pubmed: 31395440
pmcid: 6707519
doi: 10.1016/S0140-6736(19)31276-0
Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43–51.
pubmed: 24951455
doi: 10.1016/j.biopsych.2014.05.006
pmcid: 24951455
Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–18.
pubmed: 31367008
pmcid: 7055192
doi: 10.1038/s41582-019-0228-7
Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron. 2019;101(5):820–38.
pubmed: 30844401
pmcid: 6407643
doi: 10.1016/j.neuron.2019.01.056
Lane R, Feldman HH, Meyer J, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenet Genomics. 2008;18(4):289–98.
pubmed: 18334913
doi: 10.1097/FPC.0b013e3282f63f29
pmcid: 18334913
Russo P, Kisialiou A, Moroni R, et al. Effect of genetic polymorphisms (SNPs) in CHRNA7 gene on response to acetylcholinesterase inhibitors (AChEI) in patients with Alzheimer’s disease. Curr Drug Targets. 2017;18(10):1179–90.
pubmed: 26424395
doi: 10.2174/1389450116666151001111826
pmcid: 26424395
Araud T, Graw S, Berger R, et al. The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of alpha7*nAChR function. Biochem Pharmacol. 2011;82(8):904–14.
pubmed: 21718690
pmcid: 3162115
doi: 10.1016/j.bcp.2011.06.018
Gault J, Robinson M, Berger R, et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 1998;52(2):173–85.
pubmed: 9782083
doi: 10.1006/geno.1998.5363
de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, et al. Function of partially duplicated human alpha77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response. J Biol Chem. 2011;286(1):594–606.
pubmed: 21047781
doi: 10.1074/jbc.M110.180067
Ihnatovych I, Nayak TK, Ouf A, et al. iPSC model of CHRFAM7A effect on alpha7 nicotinic acetylcholine receptor function in the human context. Transl Psychiatry. 2019;9(1):59.
pubmed: 30710073
pmcid: 6358606
doi: 10.1038/s41398-019-0375-z
Sinkus ML, Graw S, Freedman R, et al. The human CHRNA7 and CHRFAM7A genes: a review of the genetics, regulation, and function. Neuropharmacology. 2015;96(Pt B):274–88.
pubmed: 25701707
pmcid: 4486515
doi: 10.1016/j.neuropharm.2015.02.006
Ma KG, Lv J, Yang WN, et al. The p38 mitogen activated protein kinase regulates beta-amyloid protein internalization through the alpha7 nicotinic acetylcholine receptor in mouse brain. Brain Res Bull. 2018;137:41–52.
pubmed: 29128415
doi: 10.1016/j.brainresbull.2017.11.006
Wang HY, Li W, Benedetti NJ, et al. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem. 2003;278(34):31547–53.
pubmed: 12801934
doi: 10.1074/jbc.M212532200
pmcid: 12801934
Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease: are we on the right road? N Engl J Med. 2014;370(4):377–8.
pubmed: 24450897
doi: 10.1056/NEJMe1313943
pmcid: 24450897
Ivanoiu A, Pariente J, Booth K, et al. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. Alzheimers Res Ther. 2016;8(1):24.
pubmed: 27334799
pmcid: 4918115
doi: 10.1186/s13195-016-0193-y
Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95.
pubmed: 32787971
pmcid: 7424995
doi: 10.1186/s13195-020-00663-w
Pankiewicz JE, Sadowski MJ. APOE genotype and Alzheimer’s immunotherapy. Oncotarget. 2017;8(25):39941–2.
pubmed: 28537920
pmcid: 5522246
doi: 10.18632/oncotarget.17990
Barrera-Ocampo A, Lopera F. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med (Cali). 2016;47(4):203–12.
pubmed: 28293044
pmcid: 5335861
doi: 10.25100/cm.v47i4.2640
Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98(6):1141-54.e7.
pubmed: 29861287
pmcid: 6023751
doi: 10.1016/j.neuron.2018.05.008
Novak P, Schmidt R, Kontsekova E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):108.
pubmed: 30355322
pmcid: 6201586
doi: 10.1186/s13195-018-0436-1